Reliance on Foreign Regulators for Drugs

Summary#

The Government of Canada published a proposed order, the Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs, on December 20, 2025. It would let Health Canada treat certain decisions or review documents from specified foreign regulators as satisfying parts of Canada's review for some new human and veterinary drugs. The goal is to speed up reviews and reduce duplicate work while keeping Canadian-specific checks.

What it does#

• Gives the Minister of Health the power to "deem" parts of a Canadian drug review complete based on a decision or documents from a listed foreign regulatory authority (FRA).
• Covers three ways this could happen:
  • General Deeming — use an FRA's decision or documents after that FRA has already authorized the foreign drug.
  • 120‑day Filing — allow a Canadian filing within 120 days of a foreign filing and rely on an expected positive FRA decision.
  • Joint Reviews — rely on documents from joint reviews that Health Canada participates in with other FRAs.
• Applies only to specific classes of drugs and to specific submission types. Those classes and the FRAs that count will be listed in a separate document (the "IbR List") that can be updated over time.
• Requires manufacturers to still file a full submission in Canada and to:
  • show the Canadian product matches the foreign one in key ways (ingredient, strength, form, route, use);
  • describe any differences and demonstrate they would not harm safety or effectiveness;
  • give labels the FRA approved and describe any post-market measures (for example, confirmatory trials) and notify Health Canada when those measures are completed.
• Keeps a set of Canadian-only checks outside the deeming process. Health Canada will always review things like Canadian labelling and, for drugs for food‑producing animals, the withdrawal period.
• Would not apply to emergency pathways (e.g., Special Access Program) or extraordinary-use submissions.
• This is a proposal (Canada Gazette, Part I). There is a public comment period of 70 days after the Part I notice, and the order would come into force if and when published in Canada Gazette, Part II; some related authorities take effect on April 1, 2027.

Who's affected#

• Drug manufacturers (innovator companies) that already pursue approvals with major foreign regulators and could use those foreign decisions to speed a Canadian authorization.
• Manufacturers of veterinary drugs and drugs for special uses that are not yet available in Canada (examples mentioned: pediatric formulations, certain companion‑animal and food‑producing animal drugs).
• Health Canada — will change how it allocates review resources and verify differences and post-market follow-ups.
• Health Technology Assessment organizations (HTAs) and the pan‑Canadian Pharmaceutical Alliance (pCPA) — they may need to adapt if approvals come earlier or if the Department's summaries change.
• Canadian generic and biosimilar makers — may be affected indirectly (competition, reference product issues); the Order keeps existing intellectual property and bioequivalence rules in place.
• Smaller Canadian companies are less likely to benefit immediately because they may not have foreign approvals to rely on.
• Patients and veterinarians could notice faster access to some drugs, depending on what classes get added to the IbR List.

Why it matters#

• Could bring some drugs to Canadians sooner by reducing duplicated review work between regulators. That may be important for products not currently authorized in Canada (for example, child‑friendly formulations or veterinary medicines).
• Health Canada plans to use the approach to free up resources to focus on the most complex or higher‑risk reviews.
• The proposal includes safeguards: manufacturers must show any differences from the foreign product won't harm safety or effectiveness, and Canadian‑specific items (like labelling and withdrawal periods) remain under Canadian review. Post‑market conditions and notifications are required.
• The department estimated a net benefit from the proposed Order: minimum quantified costs of $1.33 million (present value) or $190,104 annually, and minimum quantified benefits of $3.69 million (present value) or $525,825 annually — a minimum net benefit of $2.36 million PV or $335,721 annualized over 10 years. These are Health Canada’s estimates and depend on which drug classes and FRAs are included and on how industry uses the option.
• Important uncertainties remain: which drug classes and which foreign regulators will be listed first, how often manufacturers will use deeming (Health Canada estimates a minimum of 19 annual submissions initially), and the exact workload change for Health Canada and HTA bodies. The Order is still at the proposal stage and could change after public comments.